Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20233713
Shor B, et al. (2010) Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem 285, 15380-92 20233713
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, osteosarcoma
Relevant cell lines - cell types - tissues:  MDA-MB-361 (breast cell), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WYE132 decrease
temsirolimus decrease
temsirolimus decrease

S60-p - MAF1 (human)
Modsite: PHVLEALsPPQtsGL SwissProt Entrez-Gene
Orthologous residues
MAF1 (human): S60‑p, MAF1 (mouse): S60‑p, MAF1 (rat): S60‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, western blotting
Disease tissue studied:  bone cancer, osteosarcoma
Relevant cell lines - cell types - tissues:  293 (epithelial), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WYE132 decrease
temsirolimus decrease
mTOR (human) increase

T64-p - MAF1 (human)
Modsite: EALsPPQtsGLsPsR SwissProt Entrez-Gene
Orthologous residues
MAF1 (human): T64‑p, MAF1 (mouse): T64‑p, MAF1 (rat): T64‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, western blotting
Disease tissue studied:  bone cancer, osteosarcoma
Relevant cell lines - cell types - tissues:  293 (epithelial), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WYE132 decrease
temsirolimus decrease
mTOR (human) increase

S68-p - MAF1 (human)
Modsite: PPQtsGLsPsRLsks SwissProt Entrez-Gene
Orthologous residues
MAF1 (human): S68‑p, MAF1 (mouse): S68‑p, MAF1 (rat): S68‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, western blotting
Disease tissue studied:  bone cancer, osteosarcoma
Relevant cell lines - cell types - tissues:  293 (epithelial), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WYE132 decrease
temsirolimus decrease
mTOR (human) increase

S75-p - MAF1 (human)
Modsite: sPsRLsksQGGEEEG SwissProt Entrez-Gene
Orthologous residues
MAF1 (human): S75‑p, MAF1 (mouse): S75‑p, MAF1 (rat): S75‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer, osteosarcoma
Relevant cell lines - cell types - tissues:  293 (epithelial), MDA-MB-361 (breast cell), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WYE132 decrease
temsirolimus decrease
mTOR (human) increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, osteosarcoma
Relevant cell lines - cell types - tissues:  MDA-MB-361 (breast cell), MG63 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
WYE132 decrease
temsirolimus decrease
temsirolimus decrease